Abstract 4783
Background
Many studies have suggested that dietary calcium has a protective effect on colon cancer development. The mean dietary calcium intake of Koreans is 490 mg/day, which is far less than the recommended intake of calcium 700-800mg/day. In this study, we explored the relationship between dietary calcium intake and colorectal cancer development in Koreans with relatively low calcium intake compared to Western countries.
Methods
The Health Examinees (HEXA) Study, large-scale genomic community-based prospective cohort study was designed to identify the general characteristics of major chronic disease in Korean. Participants in this analysis consisted with 135,230 participants aged 40-69 years recruited between 2004 and 2013. The calcium intake level was categories by Dietary Reference Intakes for Koreans (KDRIs). Cox proportional hazards regression model was used to estimate hazard ratio (HR) and corresponding 95% confidence intervals (CI) for colorectal cancer risk adjusting for potential confounders.
Results
Median energy-adjusted calcium intake was 385.5mg/day in men and 420.2mg/day in women. In the multivariate-adjusted model, compared with the group consumed less than the recommended intake of calcium, the group consumed more than the recommended intake of calcium showed a marginally significant reduction in the risk of colorectal cancer in women. (HR = 0.62, 95% CI: 0.38-1.02). But, among men, no significant association were observed between the dietary calcium intake and colorectal cancer risk (HR = 0.88, 95% CI: 0.56-1.37).
Conclusions
Korean women who adhere to the recommended intake of calcium showed a reduced risk of colorectal cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Research Foundation of Korea, No. 2017R1A2B4009233.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1619 - Meta-analysis of KRAS Mutation as prognostic factor in patients (pts.) with resection of colorectal (CRC) liver metastases: Tumor burden and Sideness analysis.
Presenter: Maria Romina Luca
Session: Poster Display session 2
Resources:
Abstract
2104 - Clinical implications of regorafenib-induced hypothyroidism in metastatic colorectal cancer refractory to standard therapies: A prospective evaluation
Presenter: Jwa Hoon Kim
Session: Poster Display session 2
Resources:
Abstract
2143 - Clinical impact of BRAF V600E mutations in patients (pts) with resectable solitary colorectal liver metastases (CRLM)
Presenter: Shin Kobayashi
Session: Poster Display session 2
Resources:
Abstract
3136 - Trifluridine/tipiracil in metastatic colorectal cancer: an updated multicentre real-world analysis on efficacy, safety and predictive factors.
Presenter: Chara Stavraka
Session: Poster Display session 2
Resources:
Abstract
4234 - Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab
Presenter: Eleonora Lai
Session: Poster Display session 2
Resources:
Abstract
4287 - Safety and effectiveness of aflibercept + FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): OZONE secondary analyses
Presenter: Ian Chau
Session: Poster Display session 2
Resources:
Abstract
1820 - A Phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
Presenter: Johanna Bendell
Session: Poster Display session 2
Resources:
Abstract
5644 - Development and validation of a metastasis-associated immune prognostic model for concurrent metastatic colorectal cancer
Presenter: Zhiwen Luo
Session: Poster Display session 2
Resources:
Abstract
5697 - Prognostic role of blood cell count-based immuno-inflammatory parameters in the Valentino trial
Presenter: Giovanni Fuca
Session: Poster Display session 2
Resources:
Abstract
4704 - Evaluation of safety, immunogenicity and preliminary efficacy of PolyPEPI1018 vaccine in subjects with metastatic colorectal cancer (mCRC) with a predictive biomarker
Presenter: Joleen Hubbard
Session: Poster Display session 2
Resources:
Abstract